Research programme: oral film-based therapeutics - IntelGenx

Drug Profile

Research programme: oral film-based therapeutics - IntelGenx

Alternative Names: INT 0015/2008; INT 0037; INT 0037/2013; INT 0039/2013; INT 0040; INT 0040/2013; INT 0040/2014; INT 0041/2015; INT 0042/2015

Latest Information Update: 28 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IntelGenx Corp.
  • Class Carbolines
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Mouth disorders

Highest Development Phases

  • Research Alzheimer's disease
  • No development reported Erectile dysfunction; Panic disorder; Unspecified

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for research development in Undefined in Canada (PO, Film)
  • 28 Jun 2017 Topical oral film based products are available for licensing in USA as of 08 Jun 2017.
  • 08 Jun 2017 IntelGenx has patent protection for topical oral films, for the treatment of diseases of the oral mucosa using mucoadhesive particles
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top